River Street Advisors’s Edwards Lifesciences EW Stock Holding History

River Street Advisors’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$474K	Hold	5,240	–	–	0.14%	118
2026 Q1	$420K	Hold	5,240	–	–	0.14%	120
2025 Q4	$447K	Hold	5,240	–	–	0.17%	109
2025 Q3	$408K	Hold	5,240	–	–	0.16%	112
2025 Q2	$410K	Buy	+5,240	New	+$391K	0.18%	113

Other funds holding EW

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

River Street Advisors's EW Position: Q2 2026 in Review

River Street Advisors held its Edwards Lifesciences (EW) position steady in Q2 2026 at 5,240 shares worth $474K. The position accounts for 0.14% of the portfolio, ranked #118.

River Street Advisors first reported a position in EW in Q2 2025 and has held it in 5 quarters since. 1,327 funds tracked by Wall St. Rank hold EW as of Q2 2026.

River Street Advisors held 5,240 shares of Edwards Lifesciences worth $474K as of Q2 2026.
River Street Advisors left its Edwards Lifesciences share count unchanged in Q2 2026.
Edwards Lifesciences made up 0.14% of River Street Advisors's portfolio in Q2 2026, its #118 holding.
River Street Advisors first reported a position in Edwards Lifesciences in Q2 2025 and has held it in 5 quarters since.
1,327 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on River Street Advisors's 13F filing for Q2 2026, filed 21 Jul 2026.